Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

USFDA completes inspection of Cadila Healthcare's Ahmedabad facility

Feb 4, 2020, 19:59 IST

PTI

New Delhi, Feb 4 () Drug firm Cadila Healthcare on Tuesday said the inspection of its manufacturing facility at Ahmedabad by the US health regulator was completed with no observations.

United States Food and Drug Administration (USFDA) inspected the manufacturing facility of Alidac Pharmaceuticals, the company's wholly-owned subsidiary, at SEZ, Ahmedabad from January 27 to February 4, 2020, Cadila Healthcare said in a BSE filing.

"At the end of the inspection, no observation (483) is issued. The site manufactures oncology injectables for the regulated markets," it added.

Shares of Cadila Healthcare closed at Rs 264.05 per scrip on the BSE, up 1.46 per cent from its previous close. AKT BAL

(This story has not been edited by www.businessinsider.in and is auto–generated from a syndicated feed we subscribe to.)